MetaCap

QuidelOrtho (QDEL) vs Achieve Life Sciences (QUIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Achieve Life Sciences is the larger company by market cap ($573.2 million vs $570.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QDEL-42.94%QUIT-25.87%
+17%-15%-46%
Aug 17, 20261 yearNov 20, 2026
QDEL-43.55%QUIT-30.41%
+9%-19%-46%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QDEL versus QUIT key metrics
MetricQDELQUIT
Share price$8.32$5.56
Market cap$570.86M$573.25M
1-day change-6.73%-5.28%
YTD return-70.87%—
1-year return-65.83%—
5-year return-94.25%—
Forward P/E6.32—
EPS (TTM)$-5.39$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.73B—
Revenue growth (YoY)-1.89%—
Net income (latest FY)$-1.13B$-54.65M
Gross margin46.67%—
Operating margin-33.67%—
Net margin-41.45%—
52-week high$35.58$8.64
52-week low$8.06$2.62
Distance from 52-week high-76.62%-35.65%
Analyst consensusholdstrong_buy
Avg. price target upside+80.29%+162.23%
Average volume2.04M1.38M
Shares outstanding68.61M103.10M
Employees6,50028
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About QuidelOrtho

QDEL stock →

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

QDEL vs QUIT FAQ

Which is bigger, QuidelOrtho or Achieve Life Sciences?

Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $570.86M for QuidelOrtho (QDEL).

Are QuidelOrtho and Achieve Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons